Boston Elite
Patti Melick, chair of Wiggin and Dana LLP‘s life sciences practice, is experienced in advising life science clients in cross-border M&A, global licenses and strategic alliances, and research and development arrangements. Primarily acting for biotechnology and pharmaceutical companies, Melick notably represented BioArctic AB in its $1.35 billion global exclusive licensing deal with Bristol Myers Squibb for its PyroGlu-Aβ antibody program.
Legal 500 Editorial commentary
Accolades
Boston Elite
Mentions
Profile
Work Department
Clinical Research, Corporate, Emerging Companies and Venture Capital, Intellectual Property, Life Sciences, Mergers and Acquisitions, Private Equity
Position
Partner
Career
Patti is an accomplished life sciences lawyer who has helped numerous clients grow and bring their innovations to market over her almost 30-year career at Wiggin and Dana. She is Chair of the Life Sciences Practice and a Partner in the firm’s Corporate Department and the Mergers and Acquisitions Practice. Patti is also a member of the firm’s Pro Bono Committee and a past member of the firm’s Executive Committee. She is also a member of wiggin(x).
Patti’s work has earned multiple honors and recognition, including consistently being named a “Life Science Star” for mergers and acquisitions and for licensing and collaborations in LMG Life Sciences, Finance Monthly’s Deal Maker of the Year, and the Pro Bono Partnership’s Volunteer of the Year. She is also a James W. Cooper Fellow of the Connecticut Bar Foundation and former Vice-Chair of Women in Bio’s Metro New York Chapter.
Her extensive experience spans large multinational pharmaceutical, biotechnology, and medical device companies to world-class universities, emerging biotechnology companies, scientists, and entrepreneurs. She counsels clients in cross-border mergers and acquisitions, global licenses and strategic alliances, research and development arrangements, including clinical trial programs, manufacturing agreements and other commercial contracts.
Before joining Wiggin and Dana, Patti practiced law in the New York office of the Swedish law firm Mannheimer Swartling.
She received her J.D. from the University of Chicago Law School and graduated summa cum laude and Phi Beta Kappa from Lehigh University.
Education
- University of Chicago Law School (J.D., 1987)
- Lehigh University (B.A., 1984)
- Phi Beta Kappa
- summa cum laude
Content supplied by Wiggin and Dana LLP
Key clients
- Active Biotech AB Affibody AB Anebulo Pharmaceuticals Inc Aptar Pharma BioAegis Therapeutics Inc BioArctic AB Ferring Pharmaceuticals AS Laminar Pharmaceuticals S.A. Lytix Biopharma AS Pathos AI Inc PhotoCure ASA RallyBio LLC
Work highlights
Represented Aptar Pharma in its acquisition of all device technology assets from the proprietary portfolio of SipNose Nasal Delivery Systems, a company focused on intranasal delivery platforms for local, systemic and central nervous system indications.
Represented Aptar Pharma in its acquisition of the clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings.
Acted as lead counsel for BioArctic in its global exclusive license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program. As part of the agreement, BioArctic will receive a $100 million upfront payment and up to $1.25 billion in milestone payments (plus royalties).